Full text is available at the source.
Oral GLP-1 Medicines for Weight Loss
Updated
Abstract
The Food and Drug Administration approved oral semaglutide for type 2 diabetes in 2019.
- Oral semaglutide, along with other GLP-1 receptor agonists like danuglipron and orforglipron, is being explored for obesity treatment.
- Current effective treatments for obesity are primarily injectable medications.
- There is a significant demand for effective oral medications to enhance patient access.
- The review highlights the potential of oral semaglutide specifically for weight loss and cardiovascular health in patients with obesity.
- Future research may focus on the broader implications of oral GLP-1 receptor agonists in managing obesity.
Simplified